FAQ on BioVaxys Technology Corp. and SpayVac-for-Wildlife Inc. Expanded License Agreement
Summary
What is the main topic of the press release?
The press release announces the expansion of the license agreement between BioVaxys Technology Corp. and SpayVac-for-Wildlife Inc. to include commercial aquaculture and the farm-raised fish market, enhancing the global revenue potential of SpayVac’s fertility-control vaccines.
Why is this expansion significant?
This expansion is significant because it opens up substantial addressable markets for SpayVac’s contraceptive vaccines, offering a scalable and cost-effective solution for reproductive control in farmed fish and other animals, thereby increasing its global revenue potential.
How does SpayVac’s immunocontraceptive approach benefit aquaculture?
SpayVac’s immunocontraceptive approach benefits aquaculture by providing a single-dose, no-booster fertility-control vaccine as an alternative to triploidy, a genetic manipulation method, making it a scalable and cost-effective solution for reproductive control in farmed fish.
Who is involved in this expanded license agreement?
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) and SpayVac-for-Wildlife Inc. are involved in this expanded license agreement.
Where can I find more information about BioVaxys Technology Corp.?
More information about BioVaxys Technology Corp. can be found on their official website https://www.biovaxys.com.
What are the implications of this agreement for the global aquaculture sector?
The agreement implies a significant opportunity for the global aquaculture sector to adopt SpayVac’s contraceptive vaccines as a scalable and cost-effective solution for reproductive control, potentially leading to meaningful vaccine sales across the sector.
How does SpayVac’s vaccine compare to traditional methods like triploidy?
SpayVac’s vaccine offers a simpler, more cost-effective alternative to triploidy, requiring only a single dose without the need for boosters, unlike triploidy which involves genetic manipulation to induce sterility.
Where can I view the full press release?
The full press release can be viewed at https://ibn.fm/Uu9L4.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 119634